A capacity crunch in the US sterile fill market is driven by two factors: large pharmaceutical companies acquiring CDMO facilities for their own use, and a growing client demand for US-based manufacturing (reshoring). This creates a significant shortage and an opportunity for independent CDMOs with available capacity.

Unlike a shale well which can come online in quarters, a new LNG export facility takes four years to build. This long lead time means the market cannot quickly respond to supply disruptions, and today's investment decisions create gluts or shortages years down the line.

Companies cannot compete on labor costs in the US. According to the Reshoring Institute, if labor constitutes more than 50% of a product's build cost, it is not a candidate for US reshoring. Success hinges on automating production to extract labor, making high-capital sectors like pharma more suitable.

The ongoing wave of investment in automation and upgrading existing US facilities is not the end goal. It's the first step for companies recalculating supply chain costs due to tariffs. This "brownfield" optimization proves the economic viability of US production, paving the way for larger "greenfield" projects once existing capacity is maximized.

True economic security isn't just about production capacity; it's about having the "capability"—the qualified know-how and processes. This drastically shortens the 2-3 year time-to-recovery after a supply chain disruption, as qualifying a new fab for a specific product is the most time-consuming step.

The massive 9.1% global production surge in 2025 was a deliberate stockpiling effort to preempt tariff disruptions. The expected 2026 contraction is a natural and healthy rebalancing as companies work through this excess inventory, not a sign of industry weakness.

While tariffs affected sourcing, the COVID-19 pandemic was the main catalyst for pharma reshoring. The crisis exposed critical vulnerabilities in global supply chains for essential precursors and chemicals, creating a stronger impetus for companies to establish local manufacturing than trade policy alone.

While US tariff policies aim to bring pharmaceutical production back onshore, the immediate beneficiaries are likely to be contract manufacturers. Building new proprietary facilities is a slow and expensive process, so companies will lean on agile contract partners to quickly diversify their supply chains in the interim.

The product development J-curve in defense is brutal. Even at Anduril's accelerated pace, it takes 3-5 years and well over $100 million in investment for a single product line to go from concept to rate production and begin generating positive returns. This necessitates killing unpromising ideas very early.